GALENICAL FORMULATIONS OF ORGANIC COMPOUNDS

The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the p...

Full description

Saved in:
Bibliographic Details
Main Authors HIRSCH, STEFAN, ALTENBURGER, RALF, ADLER, SABINE, GHOSH, INDRAJIT, WOLF, MARIERISTINE, TAILLEMITE, JULIEN, WEN, HONG, BABIOLE SAUNIER, MAGGY, KELLER, PATRICE FRANCOIS, LOGGIA, NICOLETTA, KOWALSKI, JAMES, LI, SHOUFENG, TONG, WEI-QIN, VIPPAGUNTA, SUDHA, MATHARU, AMOL SINGH, BARGENDA, NICOLE, LAKSHMAN, JAY PARTHIBAN, KOCHHAR, CHARU, CURDY, CATHERINE, BOCK, MICHAELA ANNA MARIA, BUSS, BRUNO
Format Patent
LanguageEnglish
French
Published 09.04.2009
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component a) of 80% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component b) of 25% or more after 30 minutes, and 40% or more after 60 minutes at pH 4.5.
Bibliography:Application Number: CA20082698330